当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands.

Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands.

Abstract：

:To compare overall survival between women with unilateral breast cancer (UBC) and contralateral breast cancer (CBC). Women with UBC (N = 182,562; 95 %) and CBC (N = 8,912; 5 %) recorded in the Netherlands Cancer Registry between 1989 and 2008 were included and followed until 2010. We incorporated CBC as a time-dependent covariate to compute the overall mortality rate ratio between women with CBC and UBC. Prognostic factors for overall death were examined according to age at first breast cancer. Women with CBC exhibited a 30 % increase in overall mortality (Hazard Ratio (HR), 95 % Confidence Interval: 1.3, 1.3-1.4) compared with UBC, decreasing with rising age at diagnosis of first breast cancer (<50 years: 2.3, 2.2-2.5 vs. ≥70 years: 1.1, 1.0-1.1). Women older than 50 years at CBC diagnosis and diagnosed 2-5 years after their first breast cancer exhibited a 20 % higher death risk (1.2, 1.0-1.3) compared to those diagnosed within the first 2 years. In women younger than 50 years, the HR was significantly lower if the CBC was diagnosed >5 years after the first breast cancer (0.7, 0.5-0.9). The prognosis for women with CBC significantly improved over time (2004-2008: 0.6, 0.5-0.7 vs. 1989-1993). Women with CBC had a lower survival compared to women with UBC, especially those younger than 50 years at first breast cancer diagnosis. A tailored follow-up strategy beyond current recommendations is needed for these patients who, because of their age and absence of known familial risk, are currently not invited for population-based screening.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Font-Gonzalez A,Liu L,Voogd AC,Schmidt MK,Roukema JA,Coebergh JW,de Vries E,Soerjomataram I

doi

10.1007/s10549-013-2588-9

subject

Has Abstract

pub_date

2013-06-01 00:00:00

pages

811-9

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

139

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.

    abstract：PURPOSE:Studies of the etiology of inflammatory breast cancer (IBC), a rare but aggressive breast cancer, have been hampered by limited risk factor information. We extend previous studies by evaluating a broader range of risk factors. METHODS:Between 2009 and 2015, we conducted a case-control study of IBC at six cente...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05864-3

    authors： Schairer C,Hablas A,Eldein IAS,Gaafar R,Rais H,Mezlini A,Ayed FB,Ayoub WB,Benider A,Tahri A,Khouchani M,Aboulazm D,Karkouri M,Eissa S,Bastawisy AE,Yehia M,Gadalla SM,Swain SM,Merajver SD,Brown LM,Pfeiffer RM,Sol

    更新日期：2020-11-01 00:00:00

  • Dietary intake of selected fatty acids, cholesterol and carotenoids and estrogen receptor status in premenopausal breast cancer patients.

    abstract：:Although a wealth of research has focused on the influence of diet on breast cancer risk, the relationships between dietary factors and tumor characteristics of breast cancer, like estrogen receptor (ER) status, are not well characterized. In a case-case study, we evaluated self-reported dietary intake for five indivi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1016588629495

    authors： Jakovljevic J,Touillaud MS,Bondy ML,Singletary SE,Pillow PC,Chang S

    更新日期：2002-09-01 00:00:00

  • Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

    abstract：:The prognostic value of proliferative activity and its relationship with steroid hormone receptors and histopathological grade have been demonstrated for breast cancers. However, nothing is known about the underlying mechanisms. In order to understand the chronology of the appearance of increased proliferative activit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01831474

    authors： Remvikos Y,Gerbault-Seureau M,Magdelénat H,Prieur M,Dutrillaux B

    更新日期：1992-01-01 00:00:00

  • Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.

    abstract：:The mitochondrial DNA (mtDNA) 4977-bp deletion (DeltamtDNA(4977) mutation) is one of the most frequently observed mtDNA mutations in human tissues and may play a role in carcinogenesis. Only a few studies have evaluated DeltamtDNA(4977) mutation in breast cancer tissue, and the findings have been inconsistent, which m...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9613-9

    authors： Ye C,Shu XO,Wen W,Pierce L,Courtney R,Gao YT,Zheng W,Cai Q

    更新日期：2008-04-01 00:00:00

  • Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project.

    abstract：:The effect of obesity and fat distribution on survival of breast cancer patients was studied prospectively in 241 women with a natural menopause who participated in a breast cancer screening project, the DOM-project in Utrecht, The Netherlands. Mean follow-up time was 9.1 years and endpoint of interest was death from ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00665785

    authors： den Tonkelaar I,de Waard F,Seidell JC,Fracheboud J

    更新日期：1995-05-01 00:00:00

  • Diagnostic ability of different human milk fat globule antigens in breast cancer.

    abstract：:Human mammary epithelial antigens (HME-Ags) are released into the circulation by breast tumors and not by normal breast tissue (Proc. Natl. Acad. Sci. USA 74: 582-586, 1977). This characteristic made them valuable, together with other breast cancer related antigens later identified, to develop immunoassays useful in t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806353

    authors： Ceriani RL,Blank EW,Rosenbaum EH,Ben Zeev D,Lowitz RS,Johansen L,Trujillo T

    更新日期：1990-05-01 00:00:00

  • Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population.

    abstract：PURPOSE:Cytokine milieu of tumor microenvironment affects tumorigenesis in breast cancer. The aim of the present study was to investigate the potential association of functional single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer. METHODS:The study included 127 individuals comprising 40 breast c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0006-5

    authors： Kohaar I,Tiwari P,Kumar R,Nasare V,Thakur N,Das BC,Bharadwaj M

    更新日期：2009-03-01 00:00:00

  • A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.

    abstract：:Bone morphogenetic proteins (BMPs) regulate diverse cellular processes, such as proliferation, differentiation, and apoptosis. The BMPs have been studied in several cancers, but thus far contradictory results have been obtained and, especially in breast cancer, information on BMPs is still limited. We performed a syst...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9362-1

    authors： Alarmo EL,Kuukasjärvi T,Karhu R,Kallioniemi A

    更新日期：2007-06-01 00:00:00

  • Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

    abstract：BACKGROUND:Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implica...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4499-7

    authors： Leon-Ferre RA,Polley MY,Liu H,Gilbert JA,Cafourek V,Hillman DW,Elkhanany A,Akinhanmi M,Lilyquist J,Thomas A,Negron V,Boughey JC,Liu MC,Ingle JN,Kalari KR,Couch FJ,Visscher DW,Goetz MP

    更新日期：2018-01-01 00:00:00

  • Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes.

    abstract：BACKGROUND:Intracystic/encapsulated papillary carcinoma remains a poorly understood disease of the breast with a little amount of reports that describe it. It shares features with DCIS and IDC and predominantly affects postmenopausal women. This study aims to evaluate the clinical presentation, treatment, and outcomes ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05680-9

    authors： Hassan Z,Boulos F,Abbas J,El Charif MH,Assi H,Sbaity E

    更新日期：2020-07-01 00:00:00

  • A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

    abstract：PURPOSE:The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-018-4770-6

    authors： O'Shaughnessy J,DeMichele A,Ma CX,Richards P,Yardley DA,Wright GS,Kalinsky K,Steis R,Diab S,Kennealey G,Geschwindt R,Jiang W,Rugo HS

    更新日期：2018-08-01 00:00:00

  • Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system.

    abstract：:Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This re...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-013-2611-1

    authors： Russo AL,Taghian AG

    更新日期：2013-07-01 00:00:00

  • Flexible covariate effects in the proportional hazards model.

    abstract：:The proportional hazards model is frequently used in analyzing the results of clinical trials, when it is often the case that the outcomes are right-censored. This model allows one to measure treatment effects and simultaneously identify and adjust for prognostic factors that might influence the outcome. In this paper...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01840837

    authors： Hastie T,Sleeper L,Tibshirani R

    更新日期：1992-01-01 00:00:00

  • The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.

    abstract：:The basal-like or basal phenotype (BP) class of breast cancers have recently attracted attention as a poor prognostic form of breast cancer. However, BP appears to encompass biologically and clinically heterogeneous tumours, resulting in a lack of consensus definition of BP. We analysed 48,000 gene transcripts in 132 ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0450-x

    authors： Zhang H,Rakha EA,Ball GR,Spiteri I,Aleskandarany M,Paish EC,Powe DG,Macmillan RD,Caldas C,Ellis IO,Green AR

    更新日期：2010-05-01 00:00:00

  • The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

    abstract：BACKGROUND:Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation, hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we developed and tested a risk-prediction tool for cardiac toxicity in metastatic breast cancer (MBC) patients receiving chemotherapy with do...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9803-5

    authors： Dranitsaris G,Rayson D,Vincent M,Chang J,Gelmon K,Sandor D,Reardon G

    更新日期：2008-02-01 00:00:00

  • Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®.

    abstract：PURPOSE:To evaluate factors associated with compliance to the National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 testing and identify groups who are at risk of under- and over-use of BRCA1/2 testing. METHODS:Data included 20,758 women from Dr. Susan Love Research Foundation's The Health of Women (HOW)...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-5035-0

    authors： Silver MI,Klein W,Samimi G,Minasian L,Loud J,Roberts MC

    更新日期：2019-02-01 00:00:00

  • Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines.

    abstract：:Heregulin (HRG) and 17beta-estradiol (E2) interactions that modulate growth of breast cancer cell lines have recently been demonstrated. We examined the ability of heregulin beta1 (HRGbeta1) and 17beta-estradiol to modulate the biological behavior of estrogen receptor (ER) negative human breast cancer cell lines (AU-5...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006035603635

    authors： Yoo JY,Lessor T,Hamburger AW

    更新日期：1998-09-01 00:00:00

  • Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial.

    abstract：:Results from several randomised mammography screening trials have shown that it is possible to reduce mortality in breast cancer by mammographic screening at least for women above 50 years of age. The purpose of this article is to present data on mortality in breast cancer in study and control groups of the Stockholm ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1005872617944

    authors： Frisell J,Lidbrink E,Hellström L,Rutqvist LE

    更新日期：1997-09-01 00:00:00

  • Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.

    abstract：:Germline mutations in the BRCA1/2 genes account for the majority of hereditary breast ovarian cancer (HBOC). Identification of causal mutations may have significant impact on clinical management of such families. Despite high mutation detection rate, many HBOC cases remain without identified cause. These cases warrant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1325-x

    authors： Konecny M,Milly M,Zavodna K,Weismanova E,Gregorova J,Mlkva I,Ilencikova D,Kausitz J,Bartosova Z

    更新日期：2011-02-01 00:00:00

  • Clinical significance of angiogenic factors in breast cancer.

    abstract：:Growth, progression, and metastasis of breast cancer, as well as of most of the other tumors, are angiogenesis-dependent processes. Several pro-angiogenic growth factors and endogenous inhibitors of angiogenesis have been identified and sequenced, and experimental studies suggest that angiogenic activity of a tumor ma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1006175504673

    authors： Locopo N,Fanelli M,Gasparini G

    更新日期：1998-01-01 00:00:00

  • Recurrence and survival rates in British and Japanese women with breast cancer.

    abstract：:The biology of breast cancer in Japan appears to be changing in that, while post-menopausal Japanese patients have a better prognosis than comparable British women, no differences in recurrence or survival rates can now be found in pre-menopausal patients. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF02633545

    authors： Allen DS,Bulbrook RD,Chaudary MA,Hayward JL,Yoshida M,Miura S,Murai JT

    更新日期：1991-05-01 00:00:00

  • Measures of energy balance and mammographic density in the Nurses' Health Study.

    abstract：:Mammographic density is a strong risk factor for breast cancer; however the mechanism that underlies this association is unclear. We hypothesized that measures of energy balance early in life and in adulthood may be associated with mammographic density. We conducted a cross-sectional analysis of 1,398 women in the Nur...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9631-7

    authors： Samimi G,Colditz GA,Baer HJ,Tamimi RM

    更新日期：2008-05-01 00:00:00

  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

    abstract：:Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cance...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1005848921895

    authors： Tortoriello A,Facchini G,Caponigro F,Santangelo M,Benassai G,Persico G,Citarella A,Carola M,Marzano N,Iaffaioli RV

    更新日期：1998-01-01 00:00:00

  • The value of embedding: integrated palliative care for patients with metastatic breast cancer.

    abstract：PURPOSE:The American Society of Clinical Oncology recommends concurrent palliative care (PC) for patients with metastatic cancer. Recent data show benefits of early PC (at least 90 days before death). However, little is known about PC among patients who die from metastatic breast cancer. METHODS:Patients with metastat...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-017-4556-2

    authors： Rabow M,Small R,Jow A,Majure M,Chien A,Melisko M,Belkora J,Esserman LJ,Rugo H

    更新日期：2018-02-01 00:00:00

  • Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study.

    abstract：:Seroma formation after axillary lymphadenectomy in women with breast cancer remains a problem despite many efforts to reduce surgery-related morbidity. In a prospective, randomised, open, parallel-group, controlled clinical trial we evaluated the effect of a fibrin-glue coated collagen patch (TachoComb H, Nycomed Phar...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1010671209279

    authors： Berger A,Tempfer C,Hartmann B,Kornprat P,Rossmann A,Neuwirth G,Tulusan A,Kubista E

    更新日期：2001-05-01 00:00:00

  • Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer.

    abstract：:Few studies have assessed the agreement between subjects' self-report and medical records among patients with breast cancer (BC), and none has addressed this issue in low-income women with BC. We assessed the level of agreement between self-report and medical records data for key BC treatment and prognostic characteri...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0447-5

    authors： Liu Y,Diamant AL,Thind A,Maly RC

    更新日期：2010-02-01 00:00:00

  • Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo.

    abstract：:The glycolytic phenotype is a widespread phenomenon in solid cancer forms, including breast cancer. Dichloroacetate (DCA) has recently been proposed as a novel and relatively non-toxic anti-cancer agent that can reverse the glycolytic phenotype in cancer cells through the inhibition of pyruvate dehydrogenase kinase. W...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0435-9

    authors： Sun RC,Fadia M,Dahlstrom JE,Parish CR,Board PG,Blackburn AC

    更新日期：2010-02-01 00:00:00

  • Breast cancer prevention through modulation of endogenous hormones.

    abstract：:The use of exogenous sex-steroids for hormonal contraception is important to the way of life of many modern women. The widespread use of hormonal contraceptives represents a unique opportunity to have a substantial positive impact on women's health. The observation that users of oral combination type contraceptives ha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666430

    authors： Spicer DV,Pike MC

    更新日期：1993-11-01 00:00:00

  • Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.

    abstract：BACKGROUND:Three tools are currently available to predict the risk of contralateral breast cancer (CBC). We aimed to compare the performance of the Manchester formula, CBCrisk, and PredictCBC in patients with invasive breast cancer (BC). METHODS:We analyzed data of 132,756 patients (4682 CBC) from 20 international stu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05611-8

    authors： Giardiello D,Hauptmann M,Steyerberg EW,Adank MA,Akdeniz D,Blom JC,Blomqvist C,Bojesen SE,Bolla MK,Brinkhuis M,Chang-Claude J,Czene K,Devilee P,Dunning AM,Easton DF,Eccles DM,Fasching PA,Figueroa J,Flyger H,García-Cl

    更新日期：2020-06-01 00:00:00

  • Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.

    abstract：PURPOSE:To estimate the performance of diffusion-weighted imaging (DWI) for breast cancer detection. METHODS:Consecutive breast magnetic resonance imaging examinations performed from January to September 2016 were retrospectively evaluated. Examinations performed before/after neoadjuvant therapy, lacking DWI sequences...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05519-y

    authors： Rotili A,Trimboli RM,Penco S,Pesapane F,Tantrige P,Cassano E,Sardanelli F

    更新日期：2020-02-01 00:00:00